Dr. Jaya B. Kumar, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Saint Louis University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 1,543
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Saint Louis University School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME134614 -
Retina Specialist (Ophthalmology) Physician
FL license ME134614
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Halifax Health Medical Center Daytona Beach, FL
Medical groups
- Retina Vitreous Consultants (45 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,543
- Services billed
- 39,956
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 15,301 | 64 |
| Injection, aflibercept, 1 mg | 2,677 | 319 |
| Imaging of retina | 2,428 | 1,104 |
| Injection of drug into eye | 1,893 | 527 |
| Photography of the retina | 1,739 | 1,407 |
| Established patient complete exam of visual system | 1,498 | 1,103 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,418 | 95 |
| Injection, ranibizumab, 0.1 mg | 571 | 46 |
| New patient office or other outpatient visit, 45-59 minutes | 426 | 425 |
| Established patient problem focused exam of visual system | 341 | 269 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Orlando, FL | 255 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Orlando, FL | 175 |
| Latanoprost Other prescribers in Orlando, FL | 131 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Orlando, FL | 110 |
| Brimonidine Tartrate Other prescribers in Orlando, FL | 106 |
| Timolol Maleate Other prescribers in Orlando, FL | 82 |
| Ketorolac Tromethamine Other prescribers in Orlando, FL | 69 |
| Atropine Sulfate | 51 |
| Eylea (aflibercept) | 49 |
| Syfovre (pegcetacoplan/pf) | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 24 payments worth $727 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $198 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $122 |
| Ani Pharmaceuticals, Inc. | $115 |
| Genentech USA, Inc. | $107 |
| AbbVie Inc. | $85.78 |
| Astellas Pharma US Inc | $53.62 |
| Harrow Eye, LLC | $25.79 |
| Alcon Vision LLC | $18.99 |
| Food and Beverage | $727 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $120 in research payments for these studies, mostly to the institutions running them.
- NRICH
Notal Vision, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.